VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Core Viewpoint - The Schall Law Firm is investigating Voyager Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Voyager issued false or misleading statements and failed to disclose critical information to investors [2]. - On February 11, 2025, Voyager announced it would assess alternate payloads for its gene therapy program targeting SOD1 amyotrophic lateral sclerosis (ALS) [2]. - The company indicated that emerging preclinical data showed the siRNA payload component of VY9323 did not meet its standards due to an off-target effect, leading to a narrowed therapeutic window [2]. - Following this announcement, Voyager's shares dropped by 20% on the same day [2]. Group 2: Shareholder Rights - The Schall Law Firm encourages shareholders who suffered losses to participate in the investigation and offers free consultations regarding their rights [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].